Liraglutide reduces attenuation coefficient as a measure of hepatic steatosis during 16 weeks' treatment in nondiabetic obese patients: A pilot trial

BACKGROUND AND AIM: Liraglutide, a long‐acting GLP‐1 analog, is approved for the treatment of obesity with improvements in fasting blood glucose, hemoglobin A1c, and cardiovascular health. Our aim was to measure the impact of liraglutide dose for obesity on hepatic steatosis measured by ultrasound....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao Jing, Gong, Ping, Zhou, Chenyun, Huang, Chengwu, Lok, U‐Wai, Tang, Shanshan, Taylor, Ann, Eckert, Deborah, Chen, Shigao, Camilleri, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857298/
https://www.ncbi.nlm.nih.gov/pubmed/33553655
http://dx.doi.org/10.1002/jgh3.12464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857298/
https://www.ncbi.nlm.nih.gov/pubmed/33553655
http://dx.doi.org/10.1002/jgh3.12464

Ejemplares similares